Deepcell, a Silicon Valley life sciences company using artificial intelligence (AI) to identify and isolate single cells based on their morphology, has raised $73 million in Series B funding to continue to progress its unique platform.
Koch Disruptive Technologies led the round, which brings the company’s overall funding to almost $100 million. New investors Bridger Healthcare, Horizons Ventures and Casdin Capital joined the round, as well as previous investors Andreessen Horowitz and Bow Capital as well as Jeff Dean, Head of Google Brain, and Matt Mcllwain, Managing Director at Madrona Venture Group.
Spun out of Stanford University in 2017, Deepcell’s technology combines AI, microfluidics and high-resolution optics that allow isolation and collection of a vast array of single cell types. Since it was founded, the company has developed a cell atlas with over 1 billion images to analyze and sort cells based on visual morphological features.